Siemens Healthcare has announced that the U.S. Food and Drug Administration (FDA) has cleared its Artis Q and Artis Q.zen angiography system families, which feature revolutionary new X-ray tube and detector technology designed to improve minimally invasive therapy of diseases such as coronary artery disease (CAD), stroke and cancer. The new X-ray tube in both the Artis Q and Artis Q.zen can help physicians identify small vessels up to 70 percent better than conventional X-ray tube technology. The Artis Q.zen combines this X-ray source with a new detector technology that supports interventional imaging in ultra-low-dose ranges to patients, doctors and medical staff — particularly during longer interventions. With the Artis Q and Artis Q.zen system families, Siemens Healthcare again demonstrates its innovative strength and market competitiveness — key components of its Agenda 2013 two-year global Sector initiative.
